Faculty of Pharmaceutical Management & Economics, Hanoi University of Pharmacy, Hanoi, 10000, Vietnam.
Faculty of Biotechnology, Hanoi University of Pharmacy, Hanoi, 10000,Vietnam.
Pharmacogenomics. 2024;25(10-11):469-477. doi: 10.1080/14622416.2024.2385289. Epub 2024 Aug 22.
To evaluate the association between irinotecan safety and the gene polymorphism in colorectal cancer (CRC) patients. The studies were systematically searched and identified from three databases (PubMed, Embase and The Cochrane Library) until 28 February 2023. The relationships were evaluated using pooled odds ratio (OR). A total of 30 studies out of 600 were included, comprising 4471 patients. was associated with a statistically significant increase in the OR for diarrhea (OR: 1.59, 95% CI = 1.24-2.06 in the additive model; OR = 3.24, 95% CI = 2.01-5.21 in the recessive model; and OR = 1.95, 95% CI = 1.42-2.69 in the dominant model) and neutropenia (OR = 1.70, 95% CI = 1.40-2.06 in the additive model; OR = 4.10, 95%CI = 2.69-6.23 in the recessive model; and OR = 1.93, 95% CI = 1.61-2.31 in the dominant model). Subgroup analysis indicated consistent associations in both Asian and non-Asian populations. was associated with a statistically significant elevation in the OR for diarrhea (only in the recessive model, OR = 2.42; 95% CI = 1.14-5.11) and neutropenia (across all genetic models). The and alleles might be a crucial indicator for predicting irinotecan safety in CRC.
评估伊立替康安全性与结直肠癌（CRC）患者基因多态性的相关性。
系统检索PubMed、Embase 和 The Cochrane Library 三个数据库，截至 2023 年 2 月 28 日。采用合并比值比（OR）评估相关性。
共纳入 600 项研究中的 30 项，包含 4471 例患者。结果显示，与野生型相比，携带 增加腹泻（相加模型：OR=1.59，95%CI=1.24-2.06；隐性模型：OR=3.24，95%CI=2.01-5.21；显性模型：OR=1.95，95%CI=1.42-2.69）和中性粒细胞减少症（相加模型：OR=1.70，95%CI=1.40-2.06；隐性模型：OR=4.10，95%CI=2.69-6.23；显性模型：OR=1.93，95%CI=1.61-2.31）的风险比（OR）显著升高。亚组分析表明，在亚洲和非亚洲人群中均存在一致的相关性。与野生型相比，携带 增加腹泻（仅在隐性模型中，OR=2.42，95%CI=1.14-5.11）和中性粒细胞减少症（所有遗传模型中，OR=1.93，95%CI=1.61-2.31）的风险比显著升高。 等位基因可能是预测 CRC 患者伊立替康安全性的重要指标。
